Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial.
Clara I Saldarriaga, Faiez Zannad, Ciaran J McMullan, Aiwen Xing, Davis Gates, Kevin J Anstrom, Marc P Bonaca, Stefano Corda, Justin A Ezekowitz, Carolyn S P Lam, Eldrin F Lewis, JoAnn Lindenfeld, Robert J Mentz, Christopher O'Connor, Mahesh Patel, Piotr Ponikowski, Yogesh N V Reddy, Giuseppe M C Rosano, Michele Senni, James Udelson, Adriaan A Voors, Javed Butler
Eur J Heart Fail 27(8) 1426-1435
摘要
摘要
AIMS: To describe the baseline characteristics of the participants in the VICTOR (Vericiguat Global Study in Patients with Chronic Heart Failure; NCT05093933) trial and compare them to recent trials in patients with heart failure and reduced ejection fraction (HFrEF). METHODS AND RESULTS: Baseline characteristics were evaluated in 6105 patients randomized to vericiguat or placebo. The mean age of the participants was 67 ± 11 years, 23.6% were women, 64.4% were White, and 10.7% were self-identified Black. Overall, 29.1% of participants were enrolled in Latin and South America, 27.8% and 18.5% in Eastern and Western Europe, 14.0% in Asia-Pacific and 10.6% in North America. The mean left ventricular ejection fraction was 30 ± 7% and 79% had New York Heart Association class II symptoms. Mean estimated glomerular filtration rate was 70.9 ± 24.0 ml/min/1.73 m2. Median N-terminal pro-B-type natriuretic peptide level was 1476 (970-2495) pg/ml and 47.5% of participants had no prior hospitalization for heart failure. Baseline therapy included 94.4% beta-blockers, 94.3% renin-angiotensin system modulation (including 56.0% on an angiotensin receptor-neprilysin inhibitor), 77.7% mineralocorticoid receptor antagonists, 59.1% sodium-glucose cotransporter 2 inhibitors, and 32.9% implantable cardioverter-defibrillators. Overall characteristics were relatively similar to other recent HFrEF trials but the VICTOR trial enrolled a higher proportion of participants receiving contemporary drug and device therapy. CONCLUSION: The VICTOR trial enrolled the most optimally treated population in a phase III heart failure trial. These features will facilitate assessment of the benefit of vericiguat and elucidate the outcomes of patients on up-to-date medical therapy.
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(2,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。